Recruitment into Phase 2b clinical trial for scabies complete

Recruitment into Phase 2b clinical trial for scabies complete

Enrolment into Medicines Development for Global Health’s Phase 2 trial in scabies, MDGH-MOX-2002 [NCT05875441], is now complete. 200 patients were enrolled by site teams across the United States, Honduras, the Dominican Republic and El Salvador.

Our study is investigating the safety and efficacy of moxidectin as a single dose oral treatment for scabies, and results will be used to confirm dose selection before development continues. Atticus Medical is supporting this study, which is sponsored by Medicines Development for Global Health.

“Completion of enrolment brings the development of a new treatment option for this debilitating and stigmatizing disease a significant step closer,” said Dr Victoria Ryg-Cornejo, Project Leader, for our scabies program, “we are grateful for the collaboration and commitment of our study teams and study participants across the United States and Central America to reach this milestone and excited to see the outcome of data analysis.”

Read more about this program here.

-End